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Abstract
Nucleostemin is a positive regulator of cell proliferation and is highly expressed in a variety of 
stem cells, tumors, and tumor cell lines. The protein shuttles between the nucleolus and the 
nucleus in a GTP-dependent fashion. Selective depletion of intracellular guanine nucleotides by 
AVN-944, an inhibitor of the de novo purine synthetic enzyme, IMP dehydrogenase, leads to the 
rapid disappearance of nucleostemin protein in tumor cell lines, an effect that does not occur with 
two other nucleolar proteins, nucleophosmin or nucleolin. Endogenous nucleostemin protein is 
completely stabilized by MG132, an inhibitor of the 26S proteasome, as are the levels of 
expressed enhanced green fluorescent protein–tagged nucleostemin, both wild-type protein and 
protein containing mutations at the G1 GTP binding site. Nutlin-3a, a small molecule that disrupts 
the binding of the E3 ubiquitin ligase, Mdm2, to p53, stabilizes nucleostemin protein in the face of 
guanine nucleotide depletion, as does siRNA-mediated knockdown of Mdm2 expression and over-
expression of a dominant-negative form of Mdm2. Neither Doxorubicin nor Actinomycin D, 
which cause the release of nucleostemin from the nucleolus, results in nucleostemin degradation. 
We conclude that nucleostemin is a target for Mdm2-mediated ubiquitination and degradation 
when not bound to GTP. Because this effect does not occur with other chemotherapeutic agents, 
the induction of nucleostemin protein degradation in tumor cells by IMP dehydrogenase inhibition 
or by other small molecules that disrupt GTP binding may offer a new approach to the treatment 
of certain neoplastic diseases.
Introduction
Nucleostemin (NS) is a multifunctional 62 kDa protein that was initially cloned from rat 
neuronal stem cells and identified as a GTP binding protein that contains two GTP 
consensus binding sites, a G4 site at codons 177-180 and G1 P loop binding site at codons 
256-263 (1). NS is localized predominantly in the nucleolus, but as with many nucleolar 
proteins, shuttles to the nucleoplasm in response to cell cycle changes and to specific stress 
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conditions (1–5). It is highly expressed at both the RNA and protein levels in a number of 
tumor cell lines as well as in primary cancers and is more highly expressed in stem and 
progenitor cells than in differentiated cells (6, 7). The protein structure includes a highly 
basic NH2-terminal region that has been identified as a direct p53 binding region (6). 
Reduction in the expression of NS using siRNAs or by heterozygous gene knockout 
experiments is associated with decreased cell proliferation and increased cellular senescence 
(8, 9). Homozygous knockouts in murine embryonic stem cells are lethal at embryonic d 
3.5-5.5 (8). NS has thus been regarded as an important regulator of cell proliferation and is 
thought to be a direct transcriptional target of the c-myc protein (10–12).
Experiments in which GTP levels are reduced by 50% to 80% through inhibition of the de 
novo guanine nucleotide synthetic enzyme IMP dehydrogenase (IMPDH) have revealed that 
a number of nucleolar proteins are relocated to the nucleoplasm (1, 5), an event that has 
been termed the GTP-driven nucleolar cycle (2). Similar shifts of nucleolar proteins to the 
nucleoplasm also occur in response to DNA damage and to treatment of cells with 
chemotherapeutic agents such as doxorubicin. The nucleolus has thus been regarded as a 
sensor of cell stress (13), and the release of nucleolar proteins is causally related to an 
increase in p53 expression, with consequent induction of cell cycle arrest or apoptosis (14). 
A number of mechanisms have been proposed to mediate the p53 response, many of which 
seem to result from the displacement of the E3 ubiquitin ligase and tumor suppressor, 
Mdm2, from binding to p53, thus reducing the ubiquitination of p53 and its consequent 
destruction by the 26S proteasome. As one example, the nucleolar protein nucleophosmin or 
B23 upon leaving the nucleolus releases p14Arf that in turn displaces Mdm2 from p53 (15, 
16). Similarly, the ribosomal proteins L5, L11, and L23 inhibit the Mdm2–mediated 
ubiquitination of p53 in response to ribosomal stress (17–19).
We have studied the role of the potent and specific IMPDH inhibitor, AVN944, in inducing 
nucleolar stress. Previous data have shown that the decrease in GTP levels induced by this 
drug causes an egress of nucleolar proteins that is associated with inhibition of pre rRNA 
synthesis and is completely reversible with GTP repletion. This effect is also associated with 
a significant increase in both p53 and p14Arf expression and is analogous to the effects 
induced by low dose Actinomycin D, an inhibitor of RNA polymerase I (5). In addition, 
however, we have recently found that NS is rapidly degraded after GTP depletion in striking 
contrast to other nucleolar proteins. We now present data supporting a role for Mdm2 in 
ubiquitinating NS in the GTP-unbound state and targeting it for proteasomal degradation. 
Modulation of the binding of GTP to NS presents an important new avenue toward reducing 
its expression in tumor cells at the protein level and differentiates GTP-depleting agents 
such as AVN944 from other chemotherapeutic drugs that do not have this effect.
Materials and Methods
Cell culture conditions and reagents used
U2OS, MCF-7, NB4, and K562 cells were grown in DMEM or RPMI 1640 supplemented 
with 10% fetal bovine serum (HyClone; PERBIO) and 100 U/mL of penicillin and 
streptomycin. Actinomycin-D, Nutlin-3a, and Adriamycin were obtained from EMD 
Chemicals, Inc. 4’,6-Diamino-2-phenylindol (DAPI) was purchased from Molecular Probes, 
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Inc. Mouse monoclonal anti-nucleolin (MS-3), anti-p53 (DO-1), and anti-HA probe (F-7) 
antibodies and protein A/G PLUS-Agarose were from Santa Cruz Biotechnology. Rabbit 
polyclonal anti-NPM was from Cell Signaling Technology Inc. Goat Anti-Nucleostemin 
Polyclonal Antibody was from R&D Systems, Inc. Anti-actin monoclonal antibody was 
from Sigma. Full-Length A.v. Polyclonal EGFP Antibody was from Clontech Laboratories, 
Inc. Fluorescein (FITC)-conjugated donkey anti-rabbit F(ab’)2 and rhodamine-conjugated 
goat anti-mouse secondary antibodies were purchased from Jackson ImmunoResearch.
RNA isolation, cDNA synthesis, and construction of enhanced green fluorescent protein–
tagged NS
Total RNAs were extracted from U2OS cells with Trizol reagent (Invitrogen) following the 
manufacturer's instruction. Two micrograms of total RNA were used for first-strand cDNA 
synthesis using oligo (dT) as a primer for SuperScript II RNase H Reverse Transcriptase 
(SuperScript First-Strand Synthesis System for RT-PCR; Invitrogen). One tenth of the 
resulting first-strand cDNA was then used for PCR amplification with high-fidelity pfx 
DNA polymerase (Invitrogen). The primers for amplifying the entire coding sequence of NS 
are listed in Table 1. The italicized bases are the restriction enzyme sites (Xho1 and BamH1) 
with four extra bases added at each end to promote efficient digestion by the restriction 
enzymes. cDNAs of NS amplified as above were cloned into Xho1 and BamH1 site of p-
EGFP-C3 (BD; biotech), and the resulting plasmids were sequenced.
Mutagenesis of enhanced green fluorescent protein–NS, transient and stable transfection, 
and fluorescence-activated cell sorting
G261V and G261V plus G266V mutants of NS were created using the Stratagene 
QuikChange mutagenesis kit (Stratagene). The wild-type enhanced green fluorescent protein 
(EGFP)-NS construct and its GTP-binding site mutants were transiently introduced into 
U2OS cells by Superfect transfection reagent (Qiagen) according to the manufacturer's 
instruction. Twenty-four hours after transfection, the U2OS cells transfected with wild-type 
EGFP-NS were subjected to G418 selection (1 mg/mL) for 2 wk, and the EGFP-positive 
cells were then isolated by FACStar plus sorting (Becton Dickinson). Postsorting, the cells 
stably expressing EGFP-NS were collected and grown in cell growth medium.
Semiquantitative reverse transcription-PCR
RNA isolation and cDNA synthesis were conducted as described above. One tenth of the 
resulting first-strand cDNA was then used for PCR amplification. Different sets of primers 
were designed and synthesized for PCR analysis. The primer pairs used for amplifying 
human NS and cyclin-B1 are listed in Table 1. PCR products were analyzed by 1% agarose 
gel and visualized by staining with ethidium bromide.
Immunocytochemistry
U2OS cells were transiently transfected with EGFP-NS constructs (wild-type, G261V, and 
G261V plus G266V). Twenty-four hours after transfection, cells were grown on coverslips 
in 24-well plates in DMEM complete medium for 12 h and then treated with AVN-944 (1 
μmol/L) or vehicle control in the presence or absence of MG132 (5 μmol/L) for 8 h. In other 
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experiments, U2OS cells stably expressing EGFP-NS were pretreated with nutlin-3a (10 
μmol/L) for 24 h, and then exposed to AVN-944 (1 μmol/L), Act-D (5 nmol/L), or 
doxorubicin (1 μmol/L) for an additional 16 h. The cells were fixed in 4% PBS-
paraformaldehyde solution for 20 min followed by permeabilization with 0.1% Triton X-100 
in PBS for 15 min. After blocking with 5% bovine serum albumin (BSA) in PBS for 30 min, 
coverslips were inverted onto a 30-μL drop of the primary antibodies diluted in PBS 
containing 0.1% Triton-X-100 and 5% BSA (1:50 for NPM, nucleolin, and nucleostemin). 
After 1-h incubation with antibody and subsequent washing with PBS ×3 (10 min each), 
coverslips were inverted again onto 30-μL drops of the secondary antibodies diluted in PBS 
containing 5% BSA and 0.1% Triton-X 100 [rhodamine-congugated secondary antibody 
(1:300); FITC-conjugated secondary antibody (1:50)]. After washing, coverslips were 
stained with DAPI (300 nmol/L) for 5 min, washed with PBS ×3 (5 min each), mounted in 
Gel Mount Aqueous Mounting Medium (Sigma-Chemical Co.) and examined by fluorescent 
microscopy.
Western blotting
Protein lysates were prepared as described previously (5). For immunoblotting, 20 μg of 
protein lysate were electrophoresed on SDS-PAGE gels and transferred to polyvinylidene 
difluoride membrane (Immobilon-P; Millipore). Specific antigens were probed using the 
corresponding primary antibody, followed by horseradish peroxidase–conjugated secondary 
antibody. Western blots were visualized using enhanced chemiluminescence 
(Chemiluminescence Reagent Plus; Perkin-Elmer Life Sciences).
Amaxa electroporation of Mdm2 double-stranded RNA (siRNA)
Mdm2 siRNA targeting nucleotide 627 to 647 (5′-AATCAGCAGGAATCATCGGAC-3′) 
and a scrambled control oligonucleotide (5′-AAAGTCATCGTGACTACGACG-3′) were 
described previously (20). The oligonucleotides were synthesized by Qiagen, and 
electroporated into U2OS cells by using Amaxa Electroporation kit V (Amaxa) according to 
the manufacturer's instruction. Briefly, 5 × 106 cells per sample were resuspended in 100 μL 
of room temperature Nucelofector solution and then electroporated into U2OS cells using 
200 or 400 pmol of Mdm2 siRNA, scrambled control-siRNA or a mock control (Program 
X-001 on the Amaxa Nucleofector Device). Forty-eight hours after electroporation, cells 
were exposed to 1 μmol/L AVN944 or vehicle control for additional 16 h, and then analyzed 
by flow cytometry. Knockdown of Mdm2 was measured by immunoblot analysis 24 or 48 h 
posttransfection. Actin was used as a loading control.
Flow cytometry
Cells were harvested by trypsinization and washed with PBS. The cells were resuspended at 
2 × 106 cells per mL in PBS and analyzed by Flow cytometric analysis (FACS Calibur; 
Becton Dickinson). In all cases, parental U2OS cells or U2OS cells transfected with 
scrambled control-siRNA were used as negative controls.
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GTP-depletion induces selective reduction of NS protein levels
Two cell lines, MCF-7 and NB4, were treated with 1 μmol/L AVN944 and cells were 
harvested at 2-hour intervals for time periods up to 24 hours. Western blot analysis showed 
that nucleostemin protein was reduced at 4 hours and nearly absent at 8 hours in both cell 
lines, whereas nucleophosmin and nucleolin protein levels were unchanged (Fig. 1A and B). 
The AVN944-induced degradation of NS was completely prevented by pretreatment of cells 
with 50 μmol/L guanosine (data not shown). In addition, the AVN-944–induced degradation 
of NS was reversed by withdrawal of AVN-944 and by the subsequent addition of guanosine 
to replete GTP pools through the hypoxanthine-guanine phosphoribosyltransferase pathway 
(21) in the presence of AVN-944 (Fig. 1C). These results show that the AVN944-induced 
degradation of NS is dependent on GTP levels. To determine whether this effect occurs at 
the transcriptional level, reverse transcription-PCR (RT-PCR) was performed using two 
different primer sets directed at exons 1 to 6 (NS1) and exons 8 to 11 (NS2) in MCF-7 cells. 
Cyclin-B1 levels were used as an internal control. As shown in Fig. 1D, levels of mRNA 
were unchanged for NS over this time period, supporting posttranscriptional regulation. We 
next asked whether the reduction in NS protein levels could be rescued by treatment of cells 
with the proteasome inhibitor MG132. As shown in Fig. 2A and B, MG132 almost 
completely prevented the loss of NS protein at 24 hours in U2OS and K562 cell lines and 
partially reversed the loss in MCF-7 cells at 24 hours. The preventive effect of MG132 on 
NS degradation was observed at concentrations of AVN-944 up to 10 μmol/L (Fig. 2C), 
>10-fold higher than the IC50 of the drug for this cell line. These results suggest that NS 
levels are controlled by proteasome-mediated degradation.
Proteasome inhibition prevents AVN-944–induced translocation of NS and nucleolin
Because inhibition of IMPDH and subsequent nucleotide depletion has been directly 
associated with the nucleolar “stress response,” we also examined the effect of MG132 on 
the alteration in nucleolar protein distribution associated with AVN944 treatment. As shown 
in Fig. 3, AVN944 induces translocation of NS and nucleolin from the nucleolus into the 
nucleus, as shown in panel 3 (Fig. 3A). The addition of MG132 results in nucleolar retention 
of NS and, to a lesser extent, nucleolin. Of particular interest is the observation that mutation 
of human NS (NM_014366 in the National Center for Biotechnology Information nucleotide 
database) at the GTP G1 binding site (G261V and the G261V+G266V double mutant) also 
results in nucleoplasmic localization, as has been shown previously (1), and MG132 also 
localizes these mutated proteins to the nucleolus (Fig. 3B). Previous data have shown that 
the t1/2 of the protein mutated at the G1 binding site is reduced and that this mutation may 
act as a dominant negative in inducing cell death (6). Additional data (data not shown) 
obtained on EGFP-labeled protein expressed in U2OS cells show that MG-132 enhances the 
stability of the protein mutated at the G1 site. These data provide further evidence that GTP 
binding protects NS from degradation through proteasome-mediated degradation.
NS is a target of Mdm2-dependent degradation
We then asked whether Mdm2 might be responsible for NS ubiquitination and subsequent 
proteasomal degradation. This hypothesis was further suggested by the very recent finding 
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that NS binds to Mdm2, as well as to p53 (22). We therefore examined the effect of 
Nutlin-3a, a molecule that specifically binds to the p53 binding site of Mdm2 (23), on NS 
stability. Figure 4A and B show that Nutlin-3a markedly enhances the stability of EGFP-
tagged NS expressed in U2OS cells, as shown by flow cytometric analysis. A similar 
experiment performed in the absence and presence of AVN-944 (Fig. 4C) shows 
significantly enhanced fluorescence intensity resulting from nutlin-3a treatment for both 
control and AVN-944-treated cells. Western blot analysis (Fig. 4D) confirms that AVN944-
induced degradation of NS is abrogated in the presence of Nutlin-3a. As we have previously 
shown (5), AVN-944 treatment causes the accumulation of p53, as does Nutlin-3a (Fig. 4D). 
However, treatment of cells with Nutlin-3a alone does not induce the degradation of NS 
(Fig. 4D), suggesting that the accumulation of p53 is not causally related to NS degradation. 
In addition, we have found that AVN-944 induces the degradation of NS in both Raji B cells 
containing p53 mutations (213 Arg→Gln and 234 His→Tyr; ref. 24) and p53-null SaoS2 
osteosarcoma cells (data not shown; ref. 25). We conclude that p53 activity is not required 
for NS degradation.
To confirm that Mdm2 is responsible for NS degradation, we asked whether a reduction in 
Mdm2 expression would increase NS stability. A knockdown of Mdm2 expression using 
400 pmol of siRNA for 48 hours increased the levels of both endogenous and EGFP-tagged 
NS, although it did not restore them to control levels (Fig. 5A). In addition, we compared the 
effects on NS stability of expressing either wt-Mdm2 or Mdm2 containing a C464A 
mutation that inactivates the E3 ubiquitin ligase activity and serves as a dominant-negative, 
stabilizing Mdm2 substrates including p53 and the androgen receptor (26, 27). As shown in 
Fig. 5B, overexpression of wt-Mdm2 results in mildly reduced fluorescence intensity of 
EGFP-NS compared with control-transfected cells. In contrast, overexpression of C464A-
Mdm2 led to a shift toward increased fluorescence intensity (Fig. 5C), supporting a small 
dominant-negative effect on NS degradation. In addition, in data not shown, overexpression 
of wt-Mdm2 markedly enhanced the degradation of NS induced by AVN-944, whereas 
overexpression of the E3 ligase mutant decreased degradation.
Inhibition of Mdm2 by Nutlin-3a prevents the translocation of NS, nucleophosmin, and 
nucleolin induced by AVN944
Finally, we determined that nutlin-3a pretreatment relocalized NS and nucleolin to the 
nucleolus (Fig. 6A), while enhancing the expression of both Mdm2 and p53 in the nucleus 
(Fig. 6B). Importantly, the nucleoplasmic localization of NS and nucleolin induced by 
Doxorubicin and by low-dose Actinomycin D, an inhibitor of RNA polymerase I, was not 
reversible with nutlin-3a (Fig. 6C and D). These data support the conclusion that inhibition 
of the Mdm2-p53 interaction by nutlin-3a has a specific effect on preventing the degradation 
of NS induced by GTP depletion and that the nucleoplasmic localization itself is insufficient 
to account for NS instability.
We therefore propose a model in which a reduction in GTP levels induced by IMPDH 
inhibition results in NS leaving the nucleolus as a result of reduced binding of GTP to the 
protein. The resultant conformational change facilitates binding to the acidic domain of 
Mdm2. This interaction interferes with the binding of p53 to Mdm2, resulting in p53 up-
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regulation. NS is then ubiquitinated by Mdm2 and targeted to the 26S proteasome for 
degradation. This model will require further testing using in vitro assay systems.
Discussion
Depletion of intracellular ribonucleotides was first shown to induce a reversible G0-G1 cell 
cycle arrest associated with the prolonged induction of p53 and the Cdk inhibitor 
p21Waf1/Cip1 by Linke and colleagues (28). However, the mechanism by which p53 was 
activated was not well-understood at that time. More recently, the specific depletion of 
guanine ribonucleotides using inhibitors of the enzyme IMPDH has been shown to cause 
nucleolar disruption and the release of nucleolar proteins into the nucleoplasm, the so-called 
GTP-driven nucleolar cycle (1). IMPDH is the rate-limiting enzyme in the de novo synthetic 
pathway for guanine nucleotides, and inhibitors of this enzyme are effective 
immunosuppressive agents, as well as potential chemotherapeutic and antiviral drugs; the 
potent and specific inhibitor AVN944 is currently in phase I trials for the treatment of 
refractory hematologic malignancies. The release of nucleolar proteins by IMPDH inhibitors 
could thus be quite relevant to their mechanism of action. Of the nucleolar proteins studied 
to date, an increasing number including p14Arf and the ribosomal proteins L11, L5, and L23 
have been shown to displace the E3 ubiquitin ligase Mdm2 from p53, resulting in decreased 
p53 ubiquitin-dependent proteasomal degradation and increased p53 protein levels (17, 18, 
29–34). Thus, depletion of ribonucleotides, and of GTP in particular, may well cause an 
increase in p53 levels at least in part through this mechanism.
We have determined that the dramatic reduction in NS protein levels is mediated by 
proteasomal degradation of NS. NS has recently been shown to bind to Mdm2 (22). Using 
Nutlin-3a to bind to the acidic binding domain of Mdm2, the site of both p53 and NS 
binding to Mdm2, we found that NS protein levels were greatly stabilized, strongly 
implicating Mdm2 ubiquitin ligase activity as at least one mediator of NS instability. Further 
support for this conclusion comes from the enhancement of NS degradation by the 
expression of wt Mdm2 and stabilization with the expression of a dominant-negative Mdm2 
mutant. These data, together with the evidence that disruption of GTP binding to NS at the 
G1 binding site also leads to NS instability and is also rescued by MG132, lead to the 
conclusion that a conformational change in NS induced by the release of GTP increases the 
susceptibility of the protein to ubiquitination by Mdm2 and its subsequent proteasomal 
degradation. Although we were unable to obtain truly reproducible evidence of NS 
ubiquitination using HA-tagged ubiquitin in immunoprecipitation experiments, the 
preponderance of evidence strongly supports a short-lived ubiquitinated intermediate. 
Similar difficulty has been encountered in demonstrating ubiquitinated p53 under similar 
conditions (35). It is possible that the proteolysis of NS contributes to the induction of 
apoptosis by IMPDH inhibitors, suggesting a mechanism of action that is distinct from those 
of other chemotherapeutic inducers of cell stress. NS depletion through siRNA treatment 
activates p53 and increases the levels of Mdm2, a p53 target gene (22, 36). In addition, 
however, there are clearly p53-independent effects of loss of NS, as shown by the failure of 
p53-deficient cells to rescue the proliferative defect of NS–/– blastocysts (8). Thus, the 
reduction in NS protein levels that occurs with IMPDH inhibition should have broader 
effects than p53 induction, consistent with the ability of NS siRNA to inhibit the growth of 
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p53-deficient cells. The fact that NS degradation does not occur with other 
chemotherapeutic drugs that induce “nucleolar stress” suggests that there may be a unique 
effect on cell growth and/or apoptosis that results from IMPDH inhibition and GTP 
depletion. The question of whether the cellular response to NS degradation is tumor cell–
specific remains to be determined, but the increased expression of NS in tumor cells and cell 
lines suggests that tumor cells may be more dependent on NS for survival than are normal 
cells.
The binding of Nutlin-3a to Mdm2 causes a conformational change in Mdm2 (37), further 
blocking the binding of NS to Mdm2 and leading to its accumulation. We recognize, 
however, that other ubiquitin ligases may also be involved. In the case of p53, for example, 
E3 ligases including p53-induced protein with RING-H2 domain (PIRH2), constitutively 
photomorphogenic 1 (COP1), and ADP ribosylation factor–binding protein 1 (SRF-BP1) 
have also been identified as p53 ubiquitin ligases (38–40). It was proposed that these distinct 
E3 ligases may be involved in the differential regulation of p53 stability under diverse stress 
conditions or in different tissues (41). However, a dominant role of Mdm2 as a regulator of 
NS levels, even in the absence of GTP depletion, is supported by our data.
Finally, we have made the observation that Nutlin-3a pretreatment stabilizes the nucleolus 
against the release of nucleophosmin and nucleolin into the nucleoplasm, although neither of 
these proteins seems to be a substrate for proteasomal degradation. Taken together with the 
observations that mutations within the GTP binding site result in the nucleoplasmic 
localization of the NS and that MG132 treatment also stabilizes the localization of NS and 
nucleolin in the nucleolus, it is possible that the Mdm2-mediated ubiquitination of NS plays 
an important role in regulating the trafficking of other nucleolar proteins between the 
nucleolar and nucleoplasmic compartments. Intracellular GTP levels could therefore be 
pivotal in the Mdm2-dependent regulation of nucleolar protein localization.
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Effect of AVN-944 on nucleostemin protein and mRNA levels in two cell lines. A, MCF-7 
and (B) NB4 cells were exposed to 1 μmol/L AVN-944 for the times indicated. Cells were 
lysed as described in Materials and Methods, and 20 μg of total protein were loaded for 
immunoblot analysis for NS, nucleophosmin (NPM), or nucleolin; C, U2OS cells were first 
treated with AVN-944 at the concentrations indicated for 8 h, then either washed thrice and 
grown in fresh medium for an additional 16 h or continuously exposed to AVN-944 in the 
presence or absence of 50 μmol/L guanosine for 16 h. Total protein (30 μg) were loaded for 
immunoblot analysis of NS and actin. D, levels of mRNA expression of NS (NS-1 and NS-2 
used two sets of primers) and cyclin-B1 in MCF-7 cells were determined by RT-PCR.
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AVN-944–induced degradation of NS is inhibited by MG132 treatment in multiple cell 
lines. A, U2OS, MCF-7, and (B) K562 cells were treated with 1 μmol/L AVN-944 in the 
absence or presence of 5 μmol/L MG132 for 8 or 24 h. Cells were then lysed as described in 
Materials and Methods, and 20 μg of total protein were loaded for immunoblot analysis for 
NS and actin. C, U2OS cells were treated with AVN-944 at doses indicated in the absence 
or presence of 1 μmol/L MG132 for 14 h. Cells were then lysed and 20 μg of total protein 
were loaded for immunoblot analysis for NS, p53, and actin.
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MG132 treatment prevents AVN-944–induced translocation of NS and nucleolin and 
relocates GTP binding mutants of NS from the nucleoplasm to the nucleolus. A, U2OS cells 
were treated with 1 μmol/L AVN-944 in the absence or presence of 5 μmol/L MG132 for 8 
h. B, U2OS cells were transiently transfected with wild-type or two NS constructs mutated 
at the G1 binding site. Twenty-four hours after transfection, cells were treated with 5 μmol/L 
MG132 for 8 h. Cells were fixed, permeabilized, stained for nucleolin and nucleostemin, as 
described in Materials and Methods, and observed using fluorescent microscopy at ×100 
magnification.
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Effects of nutlin-3a on the stability of nucleostemin in U2OS cells stably expressing EGFP-
NS. U2OS cells and U2OS cells stably expressing EGFP-NS were pretreated with 10 
μmol/L nutlin-3a for 24 h, then exposed to 1 μmol/L AVN-944 or vehicle control for an 
additional 16 h. Quantitative assessment of EGFP-NS protein was performed by flow 
cytometry, and shown as a (A) dot plot and (B and C) histogram. In the dot plot, the plot is 
gated according to the fluorescent intensity [the FL1-height (FL1-H)] of the EGFP-tagged 
NS. In U2OS cells expressing EGFP-NS, ~40% of the total cell population are EGFP-
negative or contain undetectable level of EGFP-NS. B, the parental U2OS control cells with 
(green fine dashed lines) or without (brown fine dashed lines) nutlin-3a, respectively; the 
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EGFP-expressing U2OS cells in the absence (pink heavy solid lines) or presence (blue heavy 
solid lines) of nutlin-3a, respectively. C, control EGFP-NS–expressing U2OS cells in the 
absence (green fine solid lines) or presence (blue fine solid lines) of nutlin-3a, respectively; 
the AVN-944–treated EGFP-NS–expressing U2OS cells in the absence (brown fine solid 
lines) or presence (red fine solid lines) of nutlin-3a, respectively; the control EGFP-NS 
expressing U2OS cells in the absence (green fine dashed lines) or presence (blue fine dashed 
lines) of Nutlin-3a, respectively; the AVN-944–treated EGFP-NS expressing U2OS cells in 
the absence (brown fine dashed lines) or presence (red fine dashed lines) of nutlin-3a, 
respectively. D, Western blot of endogenous NS, p53, and EGFP-NS with or without 
nutlin-3a treatment.
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Effect of Mdm2 siRNA on NS stability in U2OS cells expressing EGFP-NS. A, U2OS cells 
were transiently transfected with 200 or 400 pmol Mdm2-siRNA, control-siRNA, or mock 
control by Amaxa electroporation. Forty-eight hours after electroporation, AVN944 (1 
μmol/L) was added for an additional 16 h, and Western blots for NS, Mdm2, p53, and actin 
were performed as described in Materials and Methods. B, U2OS cells grown in 6-well 
plates were transiently transfected with pcDNA, wild-type cytomegalovirus-Mdm2 (8 μg), 
or C464A-Mdm2 (8 μg), the E3-ligase mutant of Mdm2. Forty-eight hours after transfection, 
quantitative assessment of EGFP-NS protein was performed by flow cytometry and the 
results shown as a histogram. Blue line, the control EGFP-NS expressing U2OS cells; 
EGFP-NS–expressing U2OS cells in the presence of wt-Mdm2 (green line) and C464A-
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Mdm2 (red lines), respectively. C, U2OS cells grown in 6-well plates were transiently 
transfected with pcDNA (16 μg) or wild-type CMV-Mdm2 (16 μg). Sixty-four hours after 
transfection, quantitative assessment of EGFP-NS protein was performed by flow 
cytometry, and the results shown as a histogram. Red line, control EGFP-NS expressing 
U2OS cells; green line, EGFP-NS–expressing U2OS cells in the presence of wt-Mdm2.
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Pretreatment of U2OS cells with nutlin-3a (24 h) prevents AVN-944–induced translocation 
of NS, NPM, and nucleolin but fails to prevent Doxorubicin-or Actinomycin-D–induced 
translocation of these nucleolar proteins. U2OS cells were pretreated with 10 μmol/L 
nutlin-3 for 24 h, and then exposed to AVN-944 (1 μmol/L), Act-D (5 nmol/L), or 
doxorubicin (Dox; 1 μmol/L) for an additional 16 h (AVN-944) or 8 h (Act-D and 
doxorubicin). Cells were then fixed, permeabilized, and stained for nucleolin and NPM, as 
described in Materials and Methods, and observed using fluorescent microscopy at ×100 
magnification.
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Table 1
Sequences of primer pairs used for RT-PCR analysis
Gene Primer sequence Product (bp)
EGFP-NS 5′-agatctcgagatgaaaaggcctaagttaaagaaag-3′ (forward) 1672
5′-cggtggatcccgttacacataatctgtactgaagtc-3′ (reverse)
NS1 5′-ggcctaagttaaagaaagcaag-3′ (forward) 482
5′-ctcttctacctgaggacatc-3′ (reverse)
NS2 5′-gatctggtaccaaaggagaa-3′ ( forward) 440
5′-cttgctggacttcgcagagc-3′ (reverse)
Cyclin-B1 5′-gttgatactg cctctccaag-3′ ( forward) 474
5′-cttagtataagtgttgtcagtcac-3′ (reverse)
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